September 13, 2018
…driver of non-alcoholic steatohepatitis (NASH), a chronic and aggressive liver condition. By identifying caspase-2’s critical role, they believe an inhibitor of this enzyme could provide an effective way to stop the pathogenic progression that leads to NASH — and possibly even reverse early symptoms.
July 27, 2022
In mouse studies, UC San Diego researchers report that lactating mothers expose their feeding pups to triclosan, an antimicrobial commonly used in consumer products, resulting in early signs of liver damage.
November 23, 2020
Triclosan, an antimicrobial found in many soaps and other household items, worsens fatty liver disease in mice fed a high-fat diet.
June 27, 2022
In a pair of studies, UC San Diego School scientists have deepened investigations into the genetic origins of nonalcoholic fatty liver disease in children, describing multiple gene variants that contribute to disease risk.
January 22, 2019
Researchers at University of California San Diego School of Medicine found that a diet low in free sugars (those added to foods and beverages and occurring naturally in fruit juices) resulted in significant improvement in nonalcoholic fatty liver disease (NAFLD) in adolescent boys.
April 12, 2023
UC San Diego scientists find a protein associated with liver cancer may actually be the key to protecting against it. By blocking ferroptosis, a form of liver cell death, the protein prevents liver damage and its progression to cancer.
August 23, 2023
$9 million grant awarded to researchers with UC San Diego School of Medicine supports new study of semaglutide for liver disease.
October 28, 2020
U.S. News & World Report named University of California San Diego School of Medicine a top global university and ranked the divisions of Gastroenterology and Hepatology #1 in the world for research.
March 8, 2018
…an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings, they say, represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.
November 14, 2017
Primary liver cancer is now the second leading cause of cancer-related death worldwide, and its incidences and mortality are increasing rapidly in the United Stated. In late stages of the malignancy, there are no effective treatments or drugs. However, an unexpected finding made by a team of University of California…
